Nguyen D, de la Rochefordière A, Chauveinc L, Cosset J M, Clough K B, Beuzeboc P, Mouret-Fourme E, Guyonnet M
Département de radiothérapie, institut Curie, 26, rue d'Ulm 75005 Paris, France.
Cancer Radiother. 2002 Jun;6(4):201-8. doi: 10.1016/s1278-3218(02)00196-8.
The prognosis of locally advanced cervix cancers is poor with metastatic and local recurrence risks. Recent publications reported that concurrent chemotherapy and pelvic radiation increased local control compared to radiotherapy alone. Chemotherapy could also decrease metastatic recurrences. We report 92 cases of patients with locally advanced cervix cancer treated between 1986 and 1998 at the Institut Curie.
Concurrent chemoradiation was exclusive in 51 cases and added to surgery in 41 cases. Chemotherapy with 5FU-Cisplatin-Mitomycin C-Vindesin (protocol A) was performed for 43% of patients and 57% of them received 5FU-Cisplatin alone (protocol B).
Median follow-up was 64 months (6-149 months). Five-year disease-free survival rate was 47% and local control rate was 70%. Disease-free survival was correlated with therapeutic response. After exclusive chemoradiation, the good responsive patients had a better DFS (54% vs 26%, p = 0.018). In the surgery group, those patients with sterilized lymph nodes and tumours had also a higher DFS (76% vs 47%, p = 0.036). Toxicity was higher with protocol A.
From our study, it appears that local control of advanced cervix cancers is better with combined chemoradiotherapy but disease-free survival stays low according to the metastatic evolution. Metastasis without local recurrence remained frequent in our study. 5FU-CDDP chemotherapy has a lower toxicity and is as effective as 5FU-CDDP-Mitomycin C-Vindesin protocol, in association with radiotherapy.
局部晚期宫颈癌的预后较差,存在转移和局部复发风险。近期出版物报道,与单纯放疗相比,同步化疗和盆腔放疗可提高局部控制率。化疗还可减少转移复发。我们报告了1986年至1998年在居里研究所治疗的92例局部晚期宫颈癌患者。
51例患者仅接受同步放化疗,41例患者同步放化疗后接受手术。43%的患者采用5氟尿嘧啶-顺铂-丝裂霉素C-长春地辛方案(方案A),57%的患者仅接受5氟尿嘧啶-顺铂方案(方案B)。
中位随访时间为64个月(6 - 149个月)。5年无病生存率为47%,局部控制率为70%。无病生存与治疗反应相关。仅接受同步放化疗后,反应良好的患者无病生存率更高(54%对26%,p = 0.018)。在手术组中,淋巴结和肿瘤清除的患者无病生存率也更高(76%对47%,p = 0.036)。方案A的毒性更高。
从我们的研究来看,联合放化疗对晚期宫颈癌的局部控制效果更好,但根据转移进展情况,无病生存率仍然较低。在我们的研究中,无局部复发的转移仍然很常见。5氟尿嘧啶-顺铂化疗毒性较低,与放疗联合时与5氟尿嘧啶-顺铂-丝裂霉素C-长春地辛方案效果相同。